Protagenic Therapeutics

Protagenic Therapeutics EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Protagenic Therapeutics (PTIX) as of Nov 16, 2026 is -0.46. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 0.21 — a change of -320.43% (lower).

EV/FCF

-0.46

YoY

-320.43%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Protagenic Therapeutics is 2025 -0.46 . EV/FCF (Enterprise Value to Free Cash Flow) of Protagenic Therapeutics was 2024 0.21 . It decreases by -320.43% lower compared to the previous year.

The Protagenic Therapeutics EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-0.32 USD
Jan 1, 2019
-0.90 USD
Jan 1, 2020
-1.23 USD
Jan 1, 2021
3.25 USD
Jan 1, 2022
3.34 USD
Jan 1, 2023
0.80 USD
Jan 1, 2024
0.21 USD
Jan 1, 2025
-0.46 USD
The Protagenic Therapeutics EV/FCF history
YEAREV/FCFYoY
-0.46-320.43%
0.21-74.06%
0.80-75.98%
3.34+2.94%
3.25-363.67%
-1.23+36.62%
-0.90+178.81%
-0.32-161.49%
0.53-71.98%
1.88-174.17%
-2.53+93.76%
-1.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Protagenic Therapeutics Stock analysis

What does Protagenic Therapeutics do? Protagenic Therapeutics, Inc. develops therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound PT00114 is a synthetic TCAP-1 peptide designed to dampen overactive stress responses. The company also has a portfolio of earlier stage neuropeptides targeting the TCAP pathway in preclinical evaluation. PT00114 has shown pre-clinical efficacy in animal models of depression, anxiety, substance abuse, addiction, and PTSD, including the Saleens test for opioid withdrawal. The company focuses on developing treatments for conditions where current therapies are limited or ineffective. Protagenic's products are developed for pharmaceutical companies and research institutions seeking novel treatments for neuropsychiatric disorders. The target segments include patients suffering from depression, anxiety, PTSD, and substance abuse disorders. The company's lead compound PT00114 and its neuropeptide portfolio are positioned as potential treatments for these conditions, with the aim of addressing unmet medical needs in mental health care. Protagenic Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Protagenic Therapeutics stock

EV/FCF (Enterprise Value to Free Cash Flow) of Protagenic Therapeutics is -0.46 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Protagenic Therapeutics changed from 0.21 to -0.46, representing a -320.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Protagenic Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Protagenic Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Protagenic Therapeutics

All Key Metrics — Protagenic Therapeutics